Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

ClinicalTrials.gov ID: NCT02106832

Public ClinicalTrials.gov record NCT02106832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.

Study identification

NCT ID: NCT02106832
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 521 participants

Conditions and interventions

Conditions

Bronchiectasis

Interventions

Ciprofloxacin (BAYQ3939) dry powder for inhalation Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 29, 2014
Primary completion: Sep 12, 2016
Completion: Oct 18, 2016
Last update posted: Oct 1, 2017

2014 – 2016

United States locations

U.S. sites: 22
U.S. states: 13
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Peoria	Arizona	85381	—
Not listed	Fountain Valley	California	90708	—
Not listed	La Jolla	California	92037	—
Not listed	Long Beach	California	90813	—
Not listed	Newport Beach	California	92663	—
Not listed	San Diego	California	92120	—
Not listed	Kissimmee	Florida	34741	—
Not listed	Miami	Florida	33126	—
Not listed	Sarasota	Florida	34239	—
Not listed	Tampa	Florida	33613	—
Not listed	Decatur	Georgia	30033	—
Not listed	Skokie	Illinois	60076	—
Not listed	Olathe	Kansas	66061	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Brooklyn	New York	11229	—
Not listed	Mineola	New York	11501	—
Not listed	Asheville	North Carolina	28801	—
Not listed	Portland	Oregon	97239	—
Not listed	Doylestown	Pennsylvania	18901	—
Not listed	Greenville	South Carolina	29615	—
Not listed	Edinburg	Texas	78539	—
Not listed	Tyler	Texas	75708-3154	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 185 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02106832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 1, 2017 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02106832 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →